2,2-二甲基环丙烷-1,1-二羧酸 | 10147-54-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2,2-二甲基环丙烷-1,1-二羧酸
• 英文名称: 2,2-dimethylcyclopropane-1,1-dicarboxylic acid
• 英文别名: 2,2-Dimethyl-1,1-cyclopropandicarbonsaeure；Wgvxkbclwvekfr-uhfffaoysa-
• CAS: 10147-54-3
• 化学式: C₇H₁₀O₄
• 分子量: 158.154
• InChiKey: WGVXKBCLWVEKFR-UHFFFAOYSA-N

物化性质

• 沸点：
  326.2±25.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-二甲基环丙烷-1,1-二羧酸 在 高氯酸 作用下， 以 水 为溶剂， 生成 4.4-Dimethyl-2-carboxy-butyrolacton
  参考文献：
  名称：

  Improved Synthesis of γ-Lactones from Cyclopropyl Cyanoesters

  摘要：

  [image omitted] Cyclopropyl cyanoesters 2 were reliably converted to -lactones 4 on treatment with aqueous sulfuric acid. The cyanoesters could be easily prepared from ketones or aldehydes in two steps, making this process particularly attractive from an efficiency standpoint.

  DOI：

  10.1080/00397911.2010.501472
• 作为产物：
  描述：

  dimethyl 2,2-dimethyl-cyclopropane-1,1-dicarboxylate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 144.0h， 以87%的产率得到2,2-二甲基环丙烷-1,1-二羧酸
  参考文献：
  名称：

  Synthesis of (1S)-1-amino-2,2-dimethylcyclopropane-1-carboxylic acid via PLE mediated hydrolysis of bis(2,2,2-trifluoroethyl) 2,2-dimethylcyclopropane-1,1-dicarboxylate

  摘要：

  Hydrolysis of bis(2,2,2-trifluoroethyl) 2,2-dimethylcyclopropane-1,1-dicarboxylate with pig liver esterase afforded (1R)-2,2-dimethyl-1-(2,2,2-trifluoroethoxycarbonyl)-cyclopropane-1-carboxylic acid in high enantiomeric excess. This compound was rearranged to (1S)-2,2,2-trifluoroethyl-2,2-dimethyl-1-[(N-ethoxycarbonyl)amino]-cyclopropane-1-carboxylate via a Curtius type reaction with DPPA. Final alkaline hydrolysis gave (1S)-1-amino-2,2-dimethylcyclopropane-1-carboxylic acid. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00112-0

文献信息

• NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：AHN-GOOK PHARMACEUTICAL CO., LTD.

  公开号：US20150210635A1

  公开（公告）日：2015-07-30

  The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

  本发明涉及一种新颖的化合物或其药物可接受的盐，该化合物抑制11β-HSD1酶活性，其制备方法，以及包含该化合物作为活性成分的药物组合物。由于本发明的化合物选择性地抑制11β-HSD1（11β-羟基类固醇脱氢酶1型）的活性，因此本发明的化合物可以有效地用作治疗由11β-HSD1过度激活引起的疾病的治疗剂，例如非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由糖皮质激素过度活动介导的疾病或状况。
• THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20140221381A1

  公开（公告）日：2014-08-07

  The present invention provides a compound represented by the formula: wherein R 1 is a C 1-4 alkyl; R 2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C 1-4 alkyl and (4′) a C 1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a C 1-4 alkoxy-C 1-4 alkyl, (3′) a mono-C 1-4 alkyl-carbamoyl-C 1-4 alkyl, (4′) a C 1-4 alkoxy and (5′) a mono-C 1-4 alkylcarbamoyl-C 1-4 alkoxy, or the like; R 3 is a C 1-4 alkyl; R 4 is a C 1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.

  本发明提供了一种化合物，其表示为式：其中，R1是C1-4烷基；R2是(1)含氮的5-7元杂环基团，该基团可以具有从群组(1')卤素，(2')羟基，(3')C1-4烷基和(4')C1-4烷氧基中选择的取代基，或(2)苯基，该苯基可以具有从群组(1')卤素，(2')C1-4烷氧基-C1-4烷基，(3')单个C1-4烷基-氨基甲酰-C1-4烷基，(4')C1-4烷氧基和(5')单个C1-4烷基-氨基甲酰-C1-4烷氧基等中选择的取代基；R3是C1-4烷基；R4是C1-4烷氧基或类似物；n是1到4的整数；或其盐，作为一种具有促性腺激素释放激素拮抗活性的噻唑嘧啶化合物。
• Gem-substituted alpha v beta 3 antagonists
  申请人：——

  公开号：US20040043994A1

  公开（公告）日：2004-03-04

  The present invention relates to a class of compounds represented by the Formula I. 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or the &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I.1表示的化合物或其药学上可接受的盐，包括公式I中的化合物的药物组合物，以及选择性地抑制或拮抗αvβ3和/或αvβ5整合素的方法。
• c-MET MODULATORS AND METHOD OF USE
  申请人：BANNEN CANNE LYNNE

  公开号：US20070244116A1

  公开（公告）日：2007-10-18

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性，以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。更具体地，本发明提供了喹唑啉和喹啉，这些化合物抑制、调节和/或调节激酶受体，特别是c-Met、KDF、c-Kit、flt-3和flt-4，与上述细胞活动变化相关的信号转导途径，包含这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供制备上述化合物的方法和包含这些化合物的组合物。
• C-MET MODULATORS AND METHOD OF USE
  申请人：Bannen Canne Lynne

  公开号：US20070225307A1

  公开（公告）日：2007-09-27

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学入侵）的化合物。更具体地，该发明提供了喹唑啉和喹啉，它们能够抑制、调节和/或调节激酶受体，特别是c-Met、KDF、c-Kit、flt-3和flt-4，与上述细胞活动变化相关的信号转导途径，包含这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物和包含这些化合物的组合物的方法。

表征谱图